307 related articles for article (PubMed ID: 34547462)
1. High-dose VitC plus oncolytic adenoviruses enhance immunogenic tumor cell death and reprogram tumor immune microenvironment.
Ma J; Zhang C; Shi G; Yue D; Shu Y; Hu S; Qi Z; Chen Y; Zhang B; Zhang Y; Huang A; Su C; Zhang Y; Deng H; Cheng P
Mol Ther; 2022 Feb; 30(2):644-661. PubMed ID: 34547462
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic adenoviruses expressing checkpoint inhibitors for cancer therapy.
Xie D; Tian Y; Hu D; Wang Y; Yang Y; Zhou B; Zhang R; Ren Z; Liu M; Xu J; Dong C; Zhao B; Yang L
Signal Transduct Target Ther; 2023 Nov; 8(1):436. PubMed ID: 38016957
[TBL] [Abstract][Full Text] [Related]
3. Arming oncolytic viruses to leverage antitumor immunity.
de Gruijl TD; Janssen AB; van Beusechem VW
Expert Opin Biol Ther; 2015 Jul; 15(7):959-71. PubMed ID: 25959450
[TBL] [Abstract][Full Text] [Related]
4. CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma.
Wang G; Zhang Z; Zhong K; Wang Z; Yang N; Tang X; Li H; Lu Q; Wu Z; Yuan B; Zheng M; Cheng P; Tong A; Zhou L
Mol Ther; 2023 Jan; 31(1):134-153. PubMed ID: 36056553
[TBL] [Abstract][Full Text] [Related]
5. Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study.
Marchini A; Daeffler L; Pozdeev VI; Angelova A; Rommelaere J
Front Immunol; 2019; 10():1848. PubMed ID: 31440242
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic Immunotherapy: Can't Start a Fire Without a Spark.
Muscolini M; Tassone E; Hiscott J
Cytokine Growth Factor Rev; 2020 Dec; 56():94-101. PubMed ID: 32826166
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic adenovirus with MUC16-BiTE shows enhanced antitumor immune response by reversing the tumor microenvironment in PDX model of ovarian cancer.
Wang Q; Ma X; Wu H; Zhao C; Chen J; Li R; Yan S; Li Y; Zhang Q; Song K; Yuan C; Kong B
Oncoimmunology; 2022; 11(1):2096362. PubMed ID: 35800156
[TBL] [Abstract][Full Text] [Related]
8. A Dual-Responsive STAT3 Inhibitor Nanoprodrug Combined with Oncolytic Virus Elicits Synergistic Antitumor Immune Responses by Igniting Pyroptosis.
Su W; Qiu W; Li SJ; Wang S; Xie J; Yang QC; Xu J; Zhang J; Xu Z; Sun ZJ
Adv Mater; 2023 Mar; 35(11):e2209379. PubMed ID: 36545949
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic virotherapy against the tumor microenvironment and its potential in pancreatic cancer.
Zhang Y; Li Y; Chen K; Qian L; Wang P
J Cancer Res Ther; 2022 Sep; 18(5):1247-1255. PubMed ID: 36204869
[TBL] [Abstract][Full Text] [Related]
10. Remodeling the tumor microenvironment by oncolytic viruses: beyond oncolysis of tumor cells for cancer treatment.
Wang L; Chard Dunmall LS; Cheng Z; Wang Y
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35640930
[TBL] [Abstract][Full Text] [Related]
11. Mesenchymal stem cells and oncolytic viruses: joining forces against cancer.
Moreno R
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33558278
[TBL] [Abstract][Full Text] [Related]
12. Immunogenic cell death: The cornerstone of oncolytic viro-immunotherapy.
Palanivelu L; Liu CH; Lin LT
Front Immunol; 2022; 13():1038226. PubMed ID: 36755812
[TBL] [Abstract][Full Text] [Related]
13. Hypoxia effects on oncolytic virotherapy in Cancer: Friend or Foe?
Sadri M; Najafi A; Rahimi A; Behranvand N; Hossein Kazemi M; Khorramdelazad H; Falak R
Int Immunopharmacol; 2023 Sep; 122():110470. PubMed ID: 37433246
[TBL] [Abstract][Full Text] [Related]
14. Lighting a Fire in the Tumor Microenvironment Using Oncolytic Immunotherapy.
Achard C; Surendran A; Wedge ME; Ungerechts G; Bell J; Ilkow CS
EBioMedicine; 2018 May; 31():17-24. PubMed ID: 29724655
[TBL] [Abstract][Full Text] [Related]
15. Oncolytic virotherapy in cancer treatment: challenges and optimization prospects.
Chen L; Zuo M; Zhou Q; Wang Y
Front Immunol; 2023; 14():1308890. PubMed ID: 38169820
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxic T lymphocyte-associated protein 4 antibody aggrandizes antitumor immune response of oncolytic virus M1 via targeting regulatory T cells.
Liu W; Liu Y; Hu C; Xu C; Chen J; Chen Y; Cai J; Yan G; Zhu W
Int J Cancer; 2021 Sep; 149(6):1369-1384. PubMed ID: 34086978
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients.
Liikanen I; Ahtiainen L; Hirvinen ML; Bramante S; Cerullo V; Nokisalmi P; Hemminki O; Diaconu I; Pesonen S; Koski A; Kangasniemi L; Pesonen SK; Oksanen M; Laasonen L; Partanen K; Joensuu T; Zhao F; Kanerva A; Hemminki A
Mol Ther; 2013 Jun; 21(6):1212-23. PubMed ID: 23546299
[TBL] [Abstract][Full Text] [Related]
18. Improvement of current immunotherapies with engineered oncolytic viruses that target cancer stem cells.
Soroush A; Shahhosseini R; Ghavamikia N; Hjazi A; Roudaki S; KhalatbariLimaki M; Mirbolouk M; Pakmehr S; Karimi P
Cell Biochem Funct; 2024 Jun; 42(4):e4055. PubMed ID: 38856033
[TBL] [Abstract][Full Text] [Related]
19. IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy.
Chen T; Ding X; Liao Q; Gao N; Chen Y; Zhao C; Zhang X; Xu J
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33504576
[TBL] [Abstract][Full Text] [Related]
20. Impact of Autophagy in Oncolytic Adenoviral Therapy for Cancer.
Tazawa H; Kuroda S; Hasei J; Kagawa S; Fujiwara T
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28698504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
